LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors lessened its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 18.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 17,023 shares of the company’s stock after selling 3,750 shares during the period. Kelleher Financial Advisors owned about 0.06% of LENZ Therapeutics worth $491,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. purchased a new position in LENZ Therapeutics in the 4th quarter valued at approximately $1,270,000. Barclays PLC boosted its position in LENZ Therapeutics by 273.1% in the 3rd quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after buying an additional 12,051 shares during the period. Jane Street Group LLC purchased a new position in LENZ Therapeutics in the 3rd quarter valued at approximately $286,000. Wellington Management Group LLP purchased a new position in LENZ Therapeutics in the 3rd quarter valued at approximately $585,000. Finally, State Street Corp boosted its position in LENZ Therapeutics by 18.7% in the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after buying an additional 45,600 shares during the period. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $24.46 on Thursday. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93. The firm has a fifty day moving average price of $30.97 and a 200 day moving average price of $26.54.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the firm earned ($1.33) earnings per share. As a group, equities analysts expect that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LENZ shares. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Raymond James started coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.